Multiple sclerosis drug blocks HIV infection and transmission in human immune cells

August 13, 2020

An immunomodulatory drug called fingolimod, which is approved for the treatment of multiple sclerosis, blocks human immunodeficiency virus (HIV) infection and transmission in human immune cells, according to a study published August 13 in the open-access journal PLOS Pathogens by Postdoctoral Fellow Rachel Resop and Assistant Professor Alberto Bosque of The George Washington University, and colleagues. Although future studies in animals and humans are needed, these preliminary findings suggest that this compound may be a promising novel therapy for HIV treatment and prevention.

Nearly 40 million people worldwide currently live with HIV. Treatment of infection is lifelong, due to the ability of the virus to establish latency by integrating its genome into that of host cells, resulting in potential viral reactivation at a future time. By establishing latency, HIV evades eradication by host defense mechanisms and drug treatment. HIV is currently managed by antiretroviral drugs, which do not specifically target latent infection, may have side effects, and are of limited use in preventing transmission of the virus between individuals. For this reason, the discovery of novel strategies to target HIV infection and latency is crucial.

Bosque and colleagues investigated an alternative tactic to combat HIV infection by targeting Sphingosine-1-phosphate (S1P) receptors-- a component of the immune system involved in the progression of infection. To do so, they focused on FTY720 (fingolimod) - a well-tolerated drug that blocks the action of S1P receptors and is approved by the U.S. Food and Drug Administration. They found that FTY720 blocks HIV infection in human immune cells called CD4+ T cells by hindering multiple steps in the HIV lifecycle. For example, FTY720 reduces the density of CD4 - a protein found on the surface of T cells -- thereby inhibiting viral binding and fusion. The drug blocked HIV transmission between the cells, and consequently reduced detectable latent virus. According to the authors, the role of S1P signaling in the establishment of HIV infection, and the potential to modulate this pathway to alter the course of infection or prevent establishment of the latent reservoir in CD4+ T cells, had not been previously reported. As such, targeting the S1P pathway with FTY720 could be a novel strategy to inhibit HIV replication and reduce the latent reservoir.

The authors note, "These results indicate that Fingolimod merits further investigation as an exciting novel therapy for HIV."
Research Article

Peer-reviewed; Experimental study; Cells

Funding: Research reported in this publication was partially supported by the NIAID ( of the NIH under grants R01-AI124722, R21/R33-AI116212 to A.B. This research has been facilitated by the services and resources provided by District of Columbia, Center for AIDS research, an NIH-funded program (AI117970), which is supported by the following NIH cofunding and participating institutes and centers: NIAID, NCI, NICJD, NHLBI, NIDA, NINH, NIA, FIC, NIGGIS, NDDK, and OAR ( The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

Citation: Resop RS, Fromentin R, Newman D, Rigsby H, Dubrovsky L, Bukrinsky M, et al. (2020) Fingolimod inhibits multiple stages of the HIV-1 life cycle. PLoS Pathog 16(8): e1008679.

Author Affiliations:

Department of Microbiology, Immunology and Tropical Medicine, The

George Washington University, Washington, D.C., United States of America

Centre de recherche du CHUM and Department of microbiology, infectiology and immunology, Université de Montréal, Montreal, Canada

In your coverage please use this URL to provide access to the freely available paper:


Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to